Skip to main content

Edgewise Therapeutics, Inc. (EWTX)

NASDAQ: EWTX · Delayed Price · USD
17.30 1.41 (8.87%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap852.23M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out49.26M
EPS (ttm)-2.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume47,050
Open15.99
Previous Close15.89
Day's Range15.99 - 17.42
52-Week Range13.60 - 40.49
Betan/a
Analystsn/a
Price Target31.75 (+83.5%)
Est. Earnings DateNov 8, 2021

About EWTX

Edgewise Therapeutics' vision is to improve the lives of patients and families suffering from rare muscle disorders by building the world’s leading muscle-focused, precision medicine company. In less than four years, we have matured into a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by our holistic drug discovery approach to targeting the muscle as an organ, we have combi...

IndustryBiotechnology
IPO DateMar 26, 2021
CEOKevin Koch, Ph.D.
Employees26
Stock ExchangeNASDAQ
Ticker SymbolEWTX
Full Company Profile

Financial Performance

Financial Statements

News

Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

5 days ago - Business Wire

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

1 month ago - Business Wire

Edgewise Therapeutics Reports Second Quarter 2021 Financial Results

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

1 month ago - Business Wire

Edgewise Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 11

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

1 month ago - Business Wire

Edgewise Therapeutics to Present at the PPMD Annual Conference and the New Directions in Biology and Disease of Skele...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscl...

2 months ago - Business Wire

Losers Outnumber Gainers in Biotech IPOs This Year

Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.

Other symbols:DBTXRXRXTAK
3 months ago - GuruFocus

Edgewise Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

3 months ago - Business Wire

Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

4 months ago - Business Wire

Edgewise Therapeutics Announces Publication of Data Demonstrating the Elevation of Fast but Not Slow Skeletal Muscle ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

4 months ago - Business Wire

Edgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical Officer

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

4 months ago - Business Wire

2 Juicy Biotech Stocks to Consider Buying Right Now

They're both innovating in attractive areas where there's no competition on the radar.

Other symbols:HGEN
4 months ago - The Motley Fool

Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option t...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

5 months ago - Business Wire

Edgewise Therapeutics Announces Pricing of Initial Public Offering

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced today the ...

5 months ago - Business Wire

Rare disease biotech Edgewise Therapeutics files for a $100 million IPO

Edgewise Therapeutics, a Phase 1 biotech developing small molecule therapies for rare muscle disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

6 months ago - NASDAQ

Edgewise Therapeutics IPO Registration Document (S-1)

Edgewise Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC